Indivior PLC Ordinary Shares (INDV)
Indivior PLC is a British pharmaceutical company specializing in the development and marketing of treatments for substance use disorders, including addiction to opioids and alcohol. Founded in 2014 as a spin-off from Reckitt Benckiser, Indivior focuses on innovative medications such as Suboxone for opioid dependence. The company operates globally, providing therapies aimed at improving patient outcomes and addressing the challenges of addiction.
Company News
A comprehensive market research report analyzing the Cannabis Use Disorder pipeline, featuring over 5 companies developing novel treatments for addressing CUD challenges.
Indivior cuts its FY24 revenue guidance due to lower-than-expected SUBLOCADE revenue amid competition from a competing injectable product, leading to a decline in the company's stock price.
Indivior (INDV) delivered earnings and revenue surprises of -2.63% and 5.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
European stocks were on course for a new record high for the first time in more than two years as the semiconductor sector got a fresh leg up from Nvidia’s sparkling results.